(Q36623071)

15 August 2017

1 reference

title

Pancreatic cancer: a review of recent advances (English)

1 reference

15 August 2017

1 reference

Florian Eckel

1

1 reference

15 August 2017

Günter Schneider

series ordinal

2

1 reference

15 August 2017

Roland M Schmid

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

Expert Opinion on Investigational Drugs

15 August 2017

1 reference

15 August 2017

15

1 reference

15 August 2017

11

1 reference

15 August 2017

1395-1410

1 reference

15 August 2017

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Pancreatic cancer: basic and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Genetics and biology of pancreatic ductal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Intrinsic tumour suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Apoptosis in cancer--implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Phase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: gastrointestinal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Raltitrexed plus gemcitabine (TOMGEM) in advanced pancreatic cancer. Results of a Belgian multicentre phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

A phase II trial of raltitrexed (Tomudex) in advanced pancreatic and biliary carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Tumour necrosis factor-alpha as a tumour promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

Prognosis of Critically Ill Patients With Cancer and Acute Renal Dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.11.1395

10.1517/13543784.15.11.1395

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference